Concord Biotech (CONCORDBIO) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 revenue was INR 204 crore, down 5% year-over-year, attributed to revenue lumpiness and high sales in the preceding quarter.

• EBITDA and PAT declined due to commercialization costs of the new injectable facility at Valthera; excluding these, EBITDA margin was stable at 37% year-over-year.

• Gross margin expanded by 30 basis points year-over-year, reflecting resilient pricing and market positioning.

• Strategic initiatives included US FDA approval for teriflunomide tablets, successful regulatory inspections, and incorporation of Stellon Biotech (US) and Concord LifeGen (India) to strengthen market presence.

• Unaudited standalone and consolidated financial results for Q1 ended June 30, 2025, were approved and reviewed by the Audit Committee and Board of Directors on August 8, 2025.

Financial highlights

• Q1 FY26 consolidated revenue: INR 204 crore (down from INR 216 crore in Q1 FY25); PAT: INR 44 crore (down from INR 60 crore); EPS: INR 4.2 (down from INR 5.7).

• API revenue: INR 153.8 crore (down 10% year-over-year); Formulation revenue: INR 50.2 crore (up 12% year-over-year).

• EBITDA: INR 61 crore (vs INR 81 crore last year); EBITDA margin: 27.6% (down from 37.7%), but adjusted margin excluding injectables cost at 37%.

• Gross profit margin: 77.9% (up from 77.6%).

• Dividend of Rs. 10.70 per equity share for FY 2024-25 was declared.

Outlook and guidance

• Long-term growth strategy remains intact, with business best evaluated on an annualized basis due to inherent lumpiness.

• Expectation for injectables facility to break even by end of FY26, with ramp-up in domestic and emerging markets.

• CDMO business seen as a high-growth opportunity, targeting $40-50 million in annual revenue over the medium term.

• Management confident in achieving 25% consolidated top-line growth over the medium term, supported by capacity and differentiated strategy.

• Management anticipates positive revenue trajectory and margin improvement as new facilities contribute.